Journal

Thyroid : official journal of the American Thyroid Association
ISSN: 1557-9077
Titre abrégé: Thyroid
Pays: United States
ID NLM: 9104317

Informations de publication

Date de publication:
16 Sep 2024
Historique:
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 16 9 2024
Statut: aheadofprint

Résumé

Background Recent studies have suggested that pathogenic variants of the DICER1 gene could be a driver of alterations in some pediatric thyroid nodules, but data are still limited. The aim of this study was to detect variants in the DICER1 gene in a large cohort of pediatric thyroid nodules and then correlate them with clinicopathological data, with a focus on the disease prognosis in patients with thyroid carcinoma. Methods This retrospective cohort study consisted of 350 pediatric and young adult patients (aged 2-21 years) with thyroid nodules, from whom 275 fresh-frozen thyroid nodule samples and 92 fine-needle aspiration biopsy (FNAB) samples were collected. After an analysis of variants in major genetic alterations of thyroid tumors, variants in the DICER1 gene were identified using next-generation sequencing and multiplex ligation-dependent probe amplification methods. Peripheral blood was analyzed from patients with DICER1-positive tumors. The results of genetic analysis were then correlated with clinicopathological data. Results Variants in the DICER1 gene were detected in a total of 24/350 (6.9%; 95%CI [4.4;10.0]) pediatric and young adult patients, respectively in 10/119 (8.4%; [4.1;14.9]) patients with benign fresh-frozen tissue, in 8/141 (5.7%; [1.9;9.5]) with papillary thyroid carcinoma (PTC), and in 6/86 (7.0%; [4.1;14.6]) patients with FNAB. No other gene alteration was found in DICER1-positive samples. Germline DICER1 variants were identified in 11/24 (45.8%; [25.6;67.2]) patients. Two somatic (biallelic) variants in the DICER1 gene were found in 9/24 (37.5%; [18.8;59.4]) thyroid nodules. Somatic deletions of at least 3 Mbp long were revealed in 2/24 (8.3%; [1.0;27.0]) cases. DICER1-positive PTCs were significantly associated with the follicular subtype of PTC (p = 0.001), encapsulation (p = 0.006), and were larger in size (p = 0.035), but with no extrathyroidal extension (p = 0.039), and less frequent lymph node metastases (p = 0.003) compared to DICER1-negative PTCs. Patients with DICER1-positive PTC had an excellent response to treatment in 75% of cases. Conclusions Variants of the DICER1 gene are frequently found in the thyroid nodules of pediatric and young adult patients. In our patients, DICER1-positive PTCs showed low invasiveness. Our findings support considering more conservative management for DICER1-positive low-risk PTCs.

Identifiants

pubmed: 39283830
doi: 10.1089/thy.2024.0188
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Karolina Mastnikova (K)

Institute of Endocrinology, Department of Molecular Endocrinology, Narodni 8, Prague, Czech Republic, 110 00; kmastnikova@endo.cz.

Barbora Bulanova Pekova (B)

Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; bbulanova@endo.cz.

Vlasta Kuklikova (V)

Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; vkuklikova@endo.cz.

Eliska Vaclavikova (E)

Institute of Endocrinology, Molecular Endocrinology, Praha, Czech Republic; evaclavikova@endo.cz.

Jitka Carkova (J)

Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; jcarkova@endo.cz.

Rami Katra (R)

2nd Faculty of Medicine, Charles University and Motol University Hospital, Department of Ear, Nose and Throat, Prague, Czech Republic; rami.katra@centrum.cz.

Lucie Fialova (L)

2nd Faculty of Medicine, Charles University and Motol University Hospital, Department of Ear, Nose and Throat, Prague, Czech Republic; charovalucie@seznam.cz.

Petr Vlcek (P)

2nd Faculty of Medicine, Charles University and Motol University Hospital, Department of Nuclear Medicine and Endocrinology, Prague, Czech Republic; Petr.Vlcek@fnmotol.cz.

Daniela Kodetova (D)

Motol University Hospital, Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Prague, Czech Republic; daniela.kodetova@fnmotol.cz.

Martin Chovanec (M)

3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Department of Otorhinolaryngology, Prague, Czech Republic; martin.chovanec@fnkv.cz.

Jana Drozenova (J)

3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Department of Pathology, Prague, Czech Republic; jana.drozenova@fnkv.cz.

Radoslav Matej (R)

3rd Faculty of Medicine, Charles University, University Hospital Kralovske Vinohrady, Department of Pathology, Prague, Czech Republic; radoslav.matej@fnkv.cz.

Petra Pacesova (P)

Institute of Endocrinology, Department of Clinical Endocrinology, Prague, Czech Republic; ppacesova@endo.cz.

Zdenek Novak (Z)

Institute of Endocrinology, Department of Clinical Endocrinology, Prague, Czech Republic; novak.sono@seznam.cz.

Kristyna Procykova (K)

Institute of Endocrinology, Department of Clinical Endocrinology, Prague, Czech Republic; kprocykova@endo.cz.

Josef Vcelak (J)

Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; jvcelak@endo.cz.

Bela Bendlova (B)

Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic; bbendlova@endo.cz.

Classifications MeSH